Ardelyx
ARDX
3.26
-0.05
-1.51%
Ardelyx
US · ARDX
#3380 by market cap
3.26
-0.05
-1.51%
Live - 5344 symbols - heartbeat 471s ago
· 2026-10-08 09:08
Pre-market
3.28
+0.61%
After-hours
3.28
+0.61%
Overnight
3.26
0.00%
- Market cap
- 841.69M
- P/E (TTM)i
- -14.17
- P/Bi
- 5.65
- EPSi
- -0.26
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on ARDX?
Anonymous reader poll. Unscientific, not investment advice.
About Ardelyx
Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
- Founded
- 2007
- CEO
- Mr. Michael G. Raab
- Employees
- 489
- Headquarters
- Waltham, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- ardelyx.com
Company profile
- Exchange
- US
- Symbol
- ARDX
- Market-cap rank
- #3380
- Market cap
- 841.69M
- Float cap
- 716.10M
- Shares out
- 258.19M
- Float shares
- 219.66M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-10-08 09:08:39 · For reference only, not investment advice and not tailored to your situation.